Ind-Swift Laboratories is an API and finished-dose manufacturer based in India. It appears in 36 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with NPRA (MY), UZPHARM (UZ) and MINSA (CR). Its GMP standing is certified by EMA and CDSCO (India). Customs aggregates show $6.5M of exports covering 247 molecules to 27 destinations in 2025.
| Site | FDA FEI |
|---|---|
| S.A.S Nagar, India | Not on file |
| industrial growth centre samba, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Anastrozole | SFDA (Saudi Arabia) | 1 |
| Atorvastatin | SFDA (Saudi Arabia) | 1 |
| Clarithromycin | SFDA (Saudi Arabia) | 1 |
| Ezetimibe | SFDA (Saudi Arabia) | 1 |
| Fexofenadine | SFDA (Saudi Arabia) | 1 |
| Ivabradine | SFDA (Saudi Arabia) | 1 |
| Letrozole | SFDA (Saudi Arabia) | 1 |
| Valganciclovir | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| NPRA (MY) | 19 | None |
| UZPHARM (UZ) | 11 | None |
| MINSA (CR) | 6 | None |
| EMA | None | 6 |
| CDSCO (India) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $10.1M | 30 |
| 2025 | Not reported | $6.5M | 27 |
| 2024 | Not reported | $32.9M | 51 |
| 2023 | Not reported | $112.0M | 67 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Ind-Swift Laboratories comes back tiered against every other supplier able to file there.
Start for free